
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is poised for success with its unique PRINT technology and promising products targeting rare cardiopulmonary diseases like PH and PH-ILD. With YUTREPIA, L606, and RareGen all showing potential for strong market penetration, combined with a robust pipeline, Liquidia is well-positioned for long-term growth in a largely underpenetrated market. While there is legal risk looming with ongoing litigation regarding UTHR's patents, Liquidia's strong financials and promising data make it a sound investment for those looking for exposure in the biopharmaceutical sector.
Bears say
Liquidia is facing significant legal risks, including ongoing lawsuits that could disrupt sales of their lead product Yutrepia and potentially limit future growth. Additionally, while the company's inhaled treprostinil product may have a larger market and less competition than its other product for treatment of pulmonary arterial hypertension, there is still potential for regulatory and pricing challenges. These risks, coupled with the company's current negative cash flow and increasing competition, contribute to a negative outlook on Liquidia's stock.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares